Zydus Cadila receives approval from USFDA for Acetazolamide for Injection

17 Apr 2019 Evaluate

Zydus Cadila has received the final approval from the United States Food & Drug Administration (USFDA) to market Acetazolamide for Injection USP (US RLD-Diamox for Injection), 500 mg per single-dose vial. It will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad.

Acetazolamide is a potent carbonic anhydrase inhibitor, effective in the control of fluid secretion (e.g. some types of glaucoma), treatment of certain convulsive disorders (e. g. epilepsy) and promotion of diuresis in instances of abnormal fluid retention (e.g. cardiac edema).

The group now has 262 approvals and has so far filed over 350 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.



Zydus Lifesciences Share Price

917.95 4.05 (0.44%)
17-Dec-2025 15:14 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1795.00
Dr. Reddys Lab 1272.55
Cipla 1496.30
Zydus Lifesciences 917.95
Lupin 2111.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×